Cargando…
Multiple endocrinopathies, hypercalcaemia and pancreatitis following combined immune checkpoint inhibitor use- case report and review of literature
BACKGROUND: Immune checkpoint inhibitors (ICIs) are a novel class of oncological agents which are used to treat a number of malignancies. To date seven agents have been approved by the Food and Drug Administration (FDA) to treat both solid and haematological malignancies. Despite their efficacy they...
Autores principales: | Newman, Christine, Kgosidalwa, Oratile, Hakami, Osamah A., Kennedy, Carmel, Grogan, Liam, Agha, Amar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912868/ https://www.ncbi.nlm.nih.gov/pubmed/33639911 http://dx.doi.org/10.1186/s12902-021-00693-x |
Ejemplares similares
-
Growth Hormone Deficiency Following Traumatic Brain Injury
por: Kgosidialwa, Oratile, et al.
Publicado: (2019) -
Immune Checkpoint Inhibitor-related Endocrinopathies
por: Lu, Difei, et al.
Publicado: (2022) -
Editorial: Decoding checkpoint inhibitor-induced endocrinopathies
por: Burnett, Deborah L., et al.
Publicado: (2022) -
Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies
por: Gunawan, Florence, et al.
Publicado: (2018) -
MON-365 Immune Checkpoint Inhibitors: Endocrinopathies and Severe Electrolyte Abnormalities
por: El Mais, Rania, et al.
Publicado: (2019)